Compare · FTRE vs ILMN
FTRE vs ILMN
Side-by-side comparison of Fortrea Holdings Inc. (FTRE) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FTRE and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $40.46B, about 18.7x FTRE ($2.16B).
- ILMN has been more active in the news (8 items in the past 4 weeks vs 5 for FTRE).
- Both have 25 recent analyst ratings on file.
- Company
- Fortrea Holdings Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- $2.16B
- $40.46B
- 1M return
- +10.89%
- -
- 1Y return
- +138.45%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 5
- 8
- Recent ratings
- 25
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest FTRE
- Fortrea upgraded by Deutsche Bank with a new price target
- Fortrea upgraded by Barclays with a new price target
- Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
- Fortrea Holdings Inc. filed SEC Form 8-K: Leadership Update
- UBS initiated coverage on Fortrea with a new price target
- SEC Form 4 filed by Chief Financial Officer Knoblauch Jason Fredrick
- Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Interim CAO Russell Carrie Elizabeth converted options into 850 shares and sold $4,145 worth of shares (246 units at $16.85), increasing direct ownership by 34% to 2,384 units (SEC Form 4) (tax liability)
- Chief Operating Officer Morais Mark A. sold $53,061 worth of shares (3,149 units at $16.85) and converted options into 7,157 shares, increasing direct ownership by 5% to 81,794 units (SEC Form 4) (withholding obligation)
- Fortrea to Participate in September Investor Conferences
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)